Compare CarMax, Inc (KMX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? CarMax, Inc trades at $50.24 (market cap $7.21B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: CarMax, Inc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and CarMax, Inc is more actively traded (3,127,971 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KMX | SYRE | |
|---|---|---|
Market Cap | $7.21B | $7.52B |
Volume | 3,127,971 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $108.92 |
52-Week Low | $30.88 | $22.18 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $24.91B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $49.83, down 1.7% on the day, with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show attractive P/S of 0.26x but elevated P/E of 23.97x. Net income margin remains thin at 1.06%, though improving from previous quarters. The stock faces technical resistance at $51-$53 levels with RSI indicating potential oversold conditions.
KMX presents a mixed investment case with strong operational turnaround momentum but significant debt burden and margin pressures. The consensus price target of $60.63 offers 22% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include high leverage (debt-to-assets of 68.16%), cyclical auto market exposure, and execution of the 'Shift into GEAR' strategy. Near-term catalysts include the November strategic update webcast and continued earnings momentum.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
